| Literature DB >> 32719577 |
Abiodun Anifowose1, Ayodeji A Agbowuro1, Ravi Tripathi1, Wen Lu1, Chalet Tan2, Xiaoxiao Yang1, Binghe Wang1.
Abstract
We previously reported a series of p53-elevating anthraquinone compounds with considerable cytotoxicity for acute lymphatic leukemia (ALL) cells. To further develop this class of compounds, we examined the effect of a few key structural features on the anticancer structure-activity relationship in ALL cells. The active analogs showed comparable cytotoxicity and upregulation of p53 but did not induce significant downregulation of MDM2 as seen with the lead compound AQ-101, indicating the importance of the anthraquinone core scaffold for MDM2 regulation. The result from the current study not only contributes to the SAR framework of these anthraquinone derivatives but also opens up new chemical space for further optimization work.Entities:
Keywords: Anthraquinone; Leukemia; Structure-activity relationships; covalent inhibitor; p53
Year: 2020 PMID: 32719577 PMCID: PMC7384666 DOI: 10.1007/s00044-020-02563-y
Source DB: PubMed Journal: Med Chem Res ISSN: 1054-2523 Impact factor: 1.965